NEW YORK, April 3, 2026
MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT cell therapy agenT-797 will be presented at the AACR 2026 Annual Meeting, highlighting a novel immunotherapy combination for PD-1 refractory gastroesophageal cancer, a patient population with significant unmet clinical need.
Innovative iNKT Cell Therapy Targets Resistant Cancers
The Phase II study evaluates agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in combination with checkpoint inhibitors botensilimab and balstilimab, aiming to overcome resistance in patients who have failed prior immunotherapy. The therapy is designed as an “immune orchestrator” bridging innate and adaptive immunity, offering a differentiated approach to reactivating immune responses in difficult-to-treat tumors.
This combination represents one of the first clinical evaluations of iNKT cell therapy with dual checkpoint modulation in gastroesophageal cancer, marking a significant advancement in next-generation immuno-oncology strategies.
Phase II Trial Highlights Clinical and Scientific Potential
Advertisement
The ongoing trial, conducted at Memorial Sloan Kettering Cancer Center, focuses on patients with PD-1 refractory gastroesophageal cancer, where traditional checkpoint therapies have limited effectiveness. The study aims to generate insights into immune modulation, treatment sequencing, and durability of response, all critical factors in advancing cancer therapeutics.
Preliminary findings suggest that agenT-797 enhances peripheral T-cell activation and tumor infiltration, potentially improving clinical outcomes. The data presentation at AACR 2026 is expected to provide important evidence supporting combination immunotherapy approaches in resistant cancers and guide future clinical development strategies.
Advancing Next-Generation Immunotherapy Under GxP Frameworks
From a cGxP perspective, this development reflects strong alignment with Good Clinical Practice (GCP) through controlled Phase II trial execution and Good Manufacturing Practice (GMP) via scalable, cryopreserved production of an off-the-shelf cell therapy product. AgenT-797’s ability to reprogram the tumor microenvironment and restore immune responsiveness positions it as a promising candidate in the evolving landscape of cell and gene therapies. Additionally, the study contributes to regulatory science by informing future combination strategies and clinical endpoints, reinforcing the importance of robust clinical governance and data integrity in advanced biologics development.
Strategic Implications for Oncology Drug Development
The findings from this study are expected to influence future regulatory pathways and combination therapy design, particularly in checkpoint-refractory cancers. As resistance to immunotherapy remains a major challenge, innovative platforms like iNKT cell therapies could redefine treatment paradigms, offering new hope for patients with limited options. The AACR presentation will serve as a critical milestone in validating the clinical utility and scalability of iNKT-based therapies, supporting broader adoption in oncology pipelines and advancing precision immunotherapy approaches.
Source: MiNK Therapeutics press release
